# Epitalon

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/epitalon
Canonical HTML page: https://getbiobrief.com/entity/epitalon

## Timeline

- **2026-07-24**: PCAC Votes to Recommend Six Peptides — The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
- **2026-07-23**: FDA PCAC Public Meeting Begins — The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.

## Recent coverage (1 stories)

### FDA Panel OKs 6 Longevity Peptides for Compounding, Vanta Advances Biotech Strategy
2026-08-01 14:29:54 · Sentiment: Strongly positive · Impact: 6/10 · Sources: 2

An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
Full story: https://getbiobrief.com/story/fda-advisory-vote-six-peptides-bio-platform

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.